H.C. Wainwright raised the firm’s price target on Lyra Therapeutics (LYRA) to $16 from $2 and keeps a Neutral rating on the shares following the company’s reverse stock split.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYRA:
- Lyra Therapeutics Unveils Strategic Plans for LYR-210
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories
- Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results
- Lyra Therapeutics Announces Positive Phase 3 Trial Results
- Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint